Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Comfrey

This article was originally published in The Tan Sheet

Executive Summary

FDA "would not necessarily object" to comfrey supplements that have had pyrrolizidine alkaloids removed during processing, agency notes in recent letter to AHPA. "We would expect such a product to be completely free of the pyrrolizidine alkaloids and not simply...processed to reduce the quantity of [PAs] present," FDA says. Letter clarifies July 6 notice to eight trade groups urging marketers to recall comfrey-containing supplements due to evidence linking PAs to liver damage (1"The Tan Sheet" July 9, p. 10). However, if a principal substance is removed from a dietary ingredient, a 75-day premarket notification is required, FDA notes. AHPA is seeking data from its members on PA-free analytical methods...

You may also be interested in...



Comfrey in Canada

Health Canada warns consumers not to take products containing comfrey, or even use topical products on broken skin since the herb contains pyrrolizidine alkaloids, which may cause liver damage, agency announces Dec. 12. Health Canada's warning comes almost three years after a similar announcement by FDA. However, FDA has said it "would not necessarily object" to comfrey supplements that have had PAs removed (1"The Tan Sheet" Nov. 12, 2001, In Brief). Health Canada also reiterates warning of risks associated with kava based on independent market research survey that found such products are still offered at retail outlets despite their recall in August 2002 (2"The Tan Sheet" Aug. 22, 2002, In Brief)...

Christopher Enterprises Comfrey Marketing For Internal Use Barred

Federal Trade Commission settlement provisions that restrict marketing of, and impose warning requirements on, Christopher Enterprises' comfrey-containing supplements will not apply if the products contain no pyrrolizidine alkaloids

Kava Safety Reconsidered In Germany, FDA/Trade Associations Take Note

FDA is reconsidering kava's safety following reports the German government might ban its sale due to a possible link between the botanical and liver toxicity

Related Content

Topics

UsernamePublicRestriction

Register

PS093251

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel